We therefore propose that direct targeting of oncogenic GLI transcription factors, as has been shown in several proof of concept studies [50, 67, 68], in combination with strategies interfering with oncogenic cues promoting GLI activity in AML will provide a therapeutic benefit compared to single treatment protocols (Fig. 3). The gene discussed is GLI1; the disease is acute myeloid leukemia.